Witryna11 kwi 2024 · SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced today that four Trudhesa ® (dihydroergotamine mesylate) nasal … Witryna19 lip 2024 · SEATTLE, July 19, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing …
Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray …
Witryna24 mar 2024 · SEATTLE, March 24, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. IMPL, a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from... Witryna25 kwi 2024 · SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with... included in case rate
Impel Pharmaceuticals Announces Strategic Reprioritization,
WitrynaImpel Pharmaceuticals is actively considering partnerships, collaborations and licensing opportunities to explore the therapeutic potential of our technology and expertise with … Impel Pharmaceuticals’ mission is to create and provide transformative therapies for … Impel Pharmaceuticals has developed a proprietary drug delivery technology … The efficacy of currently approved DHE-based medications is well-established … Impel INP105 – Acute Treatment of Agitation and Aggression in Autism … Impel Pharmaceuticals is currently developing INP107, a non-invasive, self- … impel pharmaceuticals has developed its proprietary Precision Olfactory Delivery … Archive of posts categorized by Publications in Impel Pharmaceuticals. Impel … Impel attended the 2024 Headache Cooperative of the Pacific’s 14th Annual … Witryna15 lis 2024 · SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial … Witryna11 kwi 2024 · Highlights Include Multiple Presentations Addressing Safety and Efficacy of TrudhesaSEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals... Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2024 American Academy of Neurology Annual Meeting - NXT Life … included in cash